Australia's most trusted
source of pharma news
Thursday, 07 May 2026
Posted 7 May 2026 AM
The TGA is considering recent fresh developments regarding CSL Seqirus' Tavneos as the FDA proposes to withdraw market approval for the troubled drug.
Mere weeks after issuing a warning of drug induced liver injury, including eight fatal cases, related to Tavneos, the FDA is now investigating reports that scientists working for ChemoCentryx, which developed Tavneos and was later bought by Amgen, manipulated data in its submission to the FDA.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.